Jul 1, 2006
Citations
0
Influential Citations
0
Citations
Journal
Expert Opinion on Therapeutic Patents
Abstract
ANORMED, INC.: Chemokine-binding heterocyclic compound salts and methods of use thereof. A salt of N1-(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine is claimed for the modulation of CX chemokine receptor 4 (CXCR4) and CC chemokine receptor-5 (CCR5) receptor activity and the treatment of angiogenesis, HIV, arthritis, allergy, inflammatory disease, asthma and tumours. The salts have better storage stability with the p-hydroxybenzene sulfonate salt demonstrating 99.8, 99.9 and 100% stability at 70, 40 and 25°C, respectively. US20060069122 (30/03/2006) 10 pages.